Search | BIO

Home

421 Results Found

The BIO Investor Forum Links Promising Early-Stage Technologies with an Active Investor Network

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit. According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in…

New Coalition to Raise Awareness of Antimicrobial Resistance Threat, Call for Urgent Solutions

The Biotechnology Innovation Organization (BIO), leading scientists, public policy experts, and industry leaders today announced the launch of "Working to Fight AMR," a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance and advocate for policies that…

Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innovation and Patient Access

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford…

It Starts with One—Partnering Meeting Leads to Unique Public-Private Partnership

Biotech Leaders Warn: Shortsighted Policies Threaten Miracle Breakthroughs

Writing for STAT News, Paul Hastings – CEO of Nkarta Therapeutics and Vice Chair of BIO’s Board – warns that bad actors in the sector, as well as shortsighted proposals in Washington DC, threaten to derail a coming wave of biomedical innovation. Biomedical innovation is currently being…

Why Are Patients Facing Higher Costs When They Go to the Pharmacy?

BIO is out with a new whiteboard video that explores why more and more patients are facing higher costs when they go to the pharmacy to buy their prescription drugs. See how rebates and discounts within the drug cost ecosystem are often not used by insurers to lower patients’ out-of-pocket drug…

Rare Disease Drug Development Increases but Challenges Remain

In a recent study published by Tufts University, researchers found that rare disease drug development is now one of the fastest growing areas in drug R&D, with nearly one-third of all products in the global R&D pipeline targeting treatments for rare disease indications. Yet while…

BIO Briefs Geneva Audience on Science of Human Genome Editing

BIO staff recently traveled to Geneva to brief country missions and representatives from the World Health Organization (WHO), World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) on the science behind developing somatic cell genome editing medicine and its potential…

Greenwood: A Critical Medicare Policy Has Been Delayed. Let’s Use This Opportunity to Get It Right.

In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies are changing the way we treat patients with some types of cancer, policies being considered in Washington could delay access to care for individuals covered under Medicare. “While CAR-T therapies represent a…

New BIO White Paper: Incorporating Real-World Evidence Within the Label of an FDA-Approved Drug

In today’s increasingly connected world, health care researchers have access to previously unimaginable troves of data about the effects of healthcare interventions, including medicines. New technologies are allowing researchers to use so-called “big data” to investigate ways to better diagnose…

Hands putting a drop of liquid substance into a tube

Health security threats are real: What is Congress doing?

In a rare show of bipartisan agreement, Congress recently passed and yesterday President Trump signed into law legislation that will ensure the country is ready and able to respond quickly to national health security threats. As an Ebola outbreak rages on in the Democratic Republic of Congo…